295 Icosapent Ethyl Reduces Potentially Atherogenic Lipid and Inflammatory Markers in High-Risk Statin-Treated Patients with Persistent High Triglycerides, EGFR <90 Ml/Min/1.73 M^2, and Diabetes Mellitus